GT201200181A - Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas - Google Patents

Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas

Info

Publication number
GT201200181A
GT201200181A GT201200181A GT201200181A GT201200181A GT 201200181 A GT201200181 A GT 201200181A GT 201200181 A GT201200181 A GT 201200181A GT 201200181 A GT201200181 A GT 201200181A GT 201200181 A GT201200181 A GT 201200181A
Authority
GT
Guatemala
Prior art keywords
dimetoxi
pirimidin
dicloro
etil
piperazin
Prior art date
Application number
GT201200181A
Other languages
English (en)
Inventor
Berghausen Joerg
Kapa Prasad Koteswara
Mckenna Joseph
Slade Joel
Wu Raeann
Du Zhengming
Stowasser Frank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43983750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200181(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200181A publication Critical patent/GT201200181A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA PRESENTE TECNOLOGÍA PROPORCIONA NOVEDOSAS FORMAS CRISTALINAS ANHIDRAS E HIDRATADAS DE 3-(2,6-DICLORO-3,5-DIMETOXI-FENIL)-1-{6-[4-(4-ETIL-PIPERAZIN-1-IL}-FENIL-AMINO]-PIRIMIDIN-4-IL]-1-METIL-UREA, POLIMORFOS AMORFOS Y CRISTALINOS ANHIDRES DE SU SAL DE ÁCIDO MONOFOSFÓRICO, Y LA SAL DE CLORHIDRATO, INCLUYENDO SU DIHIDRATO. LA PRESENTE TECNOLOGÍA PROPORCIONA ADEMÁS MÉTODOS PARA LA PREPARACIÓN DE LAS DIFERENTES FORMAS, COMPOSICIONES QUE LAS CONTIENEN Y MÉTODOS PARA EL TRATAMIENTO MEDIANTE EL EMPLEO DE LAS MISMAS.
GT201200181A 2009-12-07 2012-06-07 Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas GT201200181A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26715509P 2009-12-07 2009-12-07

Publications (1)

Publication Number Publication Date
GT201200181A true GT201200181A (es) 2013-12-03

Family

ID=43983750

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200181A GT201200181A (es) 2009-12-07 2012-06-07 Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas

Country Status (32)

Country Link
US (1) US9067896B2 (es)
EP (1) EP2509963B1 (es)
JP (2) JP5714024B2 (es)
KR (1) KR101787784B1 (es)
CN (5) CN111269186A (es)
AR (2) AR079257A1 (es)
AU (1) AU2010328391B2 (es)
CA (1) CA2781431C (es)
CL (1) CL2012001480A1 (es)
DK (1) DK2509963T3 (es)
EC (1) ECSP12012026A (es)
ES (1) ES2562462T3 (es)
GT (1) GT201200181A (es)
HK (1) HK1171016A1 (es)
HR (1) HRP20160126T1 (es)
HU (1) HUE026983T2 (es)
IL (1) IL220012B (es)
JO (1) JO3061B1 (es)
MA (1) MA33849B1 (es)
MX (1) MX2012006562A (es)
MY (1) MY158333A (es)
NZ (3) NZ700778A (es)
PE (1) PE20121499A1 (es)
PH (1) PH12014502593A1 (es)
PL (1) PL2509963T3 (es)
RU (1) RU2572848C2 (es)
SG (1) SG10201408063SA (es)
SI (1) SI2509963T1 (es)
TN (1) TN2012000263A1 (es)
TW (1) TWI526440B (es)
WO (1) WO2011071821A1 (es)
ZA (1) ZA201203612B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN109718239A (zh) * 2012-03-30 2019-05-07 诺华股份有限公司 用于治疗低磷血性疾病的fgfr抑制剂
BR112014030812B1 (pt) 2012-06-13 2022-11-08 Incyte Holdings Corporation Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
KR102350704B1 (ko) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
EP2968337B1 (en) 2013-03-15 2021-07-21 Celgene CAR LLC Heteroaryl compounds and uses thereof
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
JP2016523973A (ja) * 2013-07-09 2016-08-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 疾患の処置のためのキナーゼ阻害物質
CN105899490B (zh) * 2013-10-18 2019-07-23 卫材R&D管理有限公司 嘧啶fgfr4抑制剂
CA2930055C (en) * 2013-12-13 2023-07-04 Novartis Ag Pharmaceutical dosage forms comprising protein kinase inhibitor
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
WO2016055916A1 (en) 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2016151501A1 (en) 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
US10562888B2 (en) 2015-04-14 2020-02-18 Eisai R&D Management Co., Ltd. Crystalline FGFR4 inhibitor compound and uses thereof
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
WO2016189472A1 (en) 2015-05-28 2016-12-01 Novartis Ag Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
TWI669300B (zh) * 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
CA3034875A1 (en) * 2016-08-23 2018-03-01 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107176954B (zh) 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
AU2018361264B2 (en) * 2017-11-01 2021-04-01 Guangdong Xianqiang Pharmaceutical Co., Ltd Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
US11583602B2 (en) 2021-06-23 2023-02-21 Kimtron, Inc. System and method for ultra-close proximity irradiation of rotating biomass
WO2023174400A1 (zh) * 2022-03-18 2023-09-21 上海润石医药科技有限公司 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
CN115785001B (zh) * 2022-11-23 2023-09-15 斯坦德药典标准物质研发(湖北)有限公司 一种英菲格拉替尼的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101242843A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 作为激酶调节剂的氨基嘧啶类化合物
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
JP5153645B2 (ja) * 2005-12-21 2013-02-27 ノバルティス アーゲー Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas

Also Published As

Publication number Publication date
CL2012001480A1 (es) 2014-09-05
NZ624315A (en) 2014-11-28
AR079257A1 (es) 2012-01-04
EP2509963A1 (en) 2012-10-17
PE20121499A1 (es) 2012-11-15
CA2781431C (en) 2017-10-31
KR20130028045A (ko) 2013-03-18
HK1171016A1 (zh) 2013-03-15
HUE026983T2 (en) 2016-08-29
NZ700778A (en) 2015-04-24
CN111100077A (zh) 2020-05-05
RU2572848C2 (ru) 2016-01-20
KR101787784B1 (ko) 2017-10-18
MY158333A (en) 2016-09-30
JP2013512956A (ja) 2013-04-18
SG10201408063SA (en) 2015-01-29
IL220012A0 (en) 2012-07-31
JO3061B1 (ar) 2017-03-15
BR112012013784A8 (pt) 2017-12-26
ZA201203612B (en) 2013-01-30
DK2509963T3 (en) 2016-02-29
CN102639510A (zh) 2012-08-15
US9067896B2 (en) 2015-06-30
AU2010328391A1 (en) 2012-06-07
JP6019142B2 (ja) 2016-11-02
PL2509963T3 (pl) 2016-05-31
SI2509963T1 (sl) 2016-05-31
CN105061332A (zh) 2015-11-18
ECSP12012026A (es) 2012-08-31
AU2010328391B2 (en) 2014-07-03
NZ600070A (en) 2014-06-27
EP2509963B1 (en) 2015-11-25
PH12014502593A1 (en) 2015-09-21
MX2012006562A (es) 2012-07-04
TN2012000263A1 (en) 2013-12-12
JP5714024B2 (ja) 2015-05-07
TWI526440B (zh) 2016-03-21
RU2012128351A (ru) 2014-01-20
CN111100078A (zh) 2020-05-05
AR114946A2 (es) 2020-11-11
HRP20160126T1 (hr) 2016-03-25
MA33849B1 (fr) 2012-12-03
WO2011071821A1 (en) 2011-06-16
CA2781431A1 (en) 2011-06-16
TW201144297A (en) 2011-12-16
IL220012B (en) 2018-02-28
CN111269186A (zh) 2020-06-12
BR112012013784A2 (pt) 2016-05-03
ES2562462T3 (es) 2016-03-04
JP2015107996A (ja) 2015-06-11
US20120245182A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
GT201200181A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il}-fenil-amino]-pirimidin-4-il]-1-metil-urea y sales de las mismas
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
ECSP13012400A (es) Pirazolo[1,5-a]pirimidinas como agentes antivirales
ECSP10010555A (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY35377A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
CL2007003187A1 (es) Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
BR112013029999A2 (pt) derivados de tiazol
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
UY34491A (es) La composición herbicida que contiene ácido de 4-amino-3-cloro-6- (4-cloro-2-flúor-3-metoxifenil) pyridina-2-carboxílico o los derivados de los mismos y fluroxipir o los derivados de los mismos
ECSP13012664A (es) Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
SV2009003286A (es) Sal de potasio cristalina de analogos de lipoxina a4
BR112012029009A2 (pt) formulações líquidas de fumarato de rupatadina
GT201300089A (es) Nuevas formas cristalinas de la sal sodica del acido (4-(4-(5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il)-fenil)-ciclohexil)-acetico
PA8798401A1 (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY35685A (es) Compuestos de dióxido de amino tiazina bicíclicos puenteados como inhibidores de beta-secretasa y sus métodos de uso
MX343517B (es) 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
BR112015020825A2 (pt) combinações de agentes antimicrobianos sinérgicas contendo dióxido de cloro e ácido orgânico úteis para controlar microrganismos em processos industriais